Department of Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
PLoS Genet. 2012;8(11):e1003027. doi: 10.1371/journal.pgen.1003027. Epub 2012 Nov 15.
Breast cancers that are "triple-negative" for the clinical markers ESR1, PGR, and HER2 typically belong to the Basal-like molecular subtype. Defective Rb, p53, and Brca1 pathways are each associated with triple-negative and Basal-like subtypes. Our mouse genetic studies demonstrate that the combined inactivation of Rb and p53 pathways is sufficient to suppress the physiological cell death of mammary involution. Furthermore, concomitant inactivation of all three pathways in mammary epithelium has an additive effect on tumor latency and predisposes highly penetrant, metastatic adenocarcinomas. The tumors are poorly differentiated and have histologic features that are common among human Brca1-mutated tumors, including heterogeneous morphology, metaplasia, and necrosis. Gene expression analyses demonstrate that the tumors share attributes of both Basal-like and Claudin-low signatures, two molecular subtypes encompassed by the broader, triple-negative class defined by clinical markers.
乳腺癌在临床标志物 ESR1、PGR 和 HER2 上呈“三阴性”,通常属于基底样分子亚型。Rb、p53 和 Brca1 通路的缺陷均与三阴性和基底样亚型相关。我们的小鼠遗传研究表明,Rb 和 p53 通路的联合失活足以抑制乳腺退化的生理性细胞死亡。此外,乳腺上皮中所有三种途径的同时失活对肿瘤潜伏期有累加效应,并使高穿透性、转移性腺癌易感。肿瘤分化不良,具有组织学特征,在人类 Brca1 突变肿瘤中很常见,包括形态异质性、化生和坏死。基因表达分析表明,这些肿瘤具有基底样和 Claudin-low 特征的共同属性,这两种分子亚型均包含在临床标志物定义的更广泛的三阴性类别中。